Safety, tolerability, and efficacy of fixed combination therapy with dorzolamide hydrochloride 2% and timolol maleate 0.5% in glaucoma and ocular hypertension

Nicholas P Bell, Jos&eacute; L Ramos, Robert M FeldmanRobert Cizik Eye Clinic, Department of Ophthalmology and Visual Science, The University of Texas Medical School at Houston, Houston, Texas 77030, USAAbstract: Glaucoma is a collection of diseases characterized by multifactorial progressiv...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Nicholas P Bell, Jos&eacute; L Ramos, Robert M Feldman
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2010
Materias:	Ophthalmology RE1-994
Acceso en línea:	https://doaj.org/article/abf43b91af4442e783570dc823038032
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:abf43b91af4442e783570dc823038032
record_format	dspace
spelling	oai:doaj.org-article:abf43b91af4442e783570dc8230380322021-12-02T02:13:11ZSafety, tolerability, and efficacy of fixed combination therapy with dorzolamide hydrochloride 2% and timolol maleate 0.5% in glaucoma and ocular hypertension1177-54671177-5483https://doaj.org/article/abf43b91af4442e783570dc8230380322010-11-01T00:00:00Zhttp://www.dovepress.com/safety-tolerability-and-efficacy-of-fixed-combination-therapy-with-dor-a5710https://doaj.org/toc/1177-5467https://doaj.org/toc/1177-5483Nicholas P Bell, Jos&eacute; L Ramos, Robert M FeldmanRobert Cizik Eye Clinic, Department of Ophthalmology and Visual Science, The University of Texas Medical School at Houston, Houston, Texas 77030, USAAbstract: Glaucoma is a collection of diseases characterized by multifactorial progressive changes leading to visual field loss and optic neuropathy most frequently due to elevated intraocular pressure (IOP). The goal of treatment is the lowering of the IOP to prevent additional optic nerve damage. Treatment usually begins with topical pharmacological agents as monotherapy, progresses to combination therapy with agents from up to 4 different classes of IOP-lowering medications, and then proceeds to laser or incisional surgical modalities for refractory cases. The fixed combination therapy with the carbonic anhydrase inhibitor dorzolamide hydrochloride 2% and the beta blocker timolol maleate 0.5% is now available in a generic formulation for the treatment of patients who have not responded sufficiently to monotherapy with beta adrenergic blockers. In pre- and postmarketing clinical studies, the fixed combination dorzolamide&ndash;timolol has been shown to be safe and efficacious, and well tolerated by patients. The fixed combination dorzolamide&ndash;timolol is convenient for patients, reduces their dosing regimen with the goal of increasing their compliance, reduces the effects of &ldquo;washout&rdquo; when instilling multiple drops, and reduces the preservative burden by reducing the number of drops administered per day.Keywords: dorzolamide, timolol, glaucoma, ocular hypertension, elevated IOP, fixed combination therapy Nicholas P BellJos&eacute; L RamosRobert M FeldmanDove Medical PressarticleOphthalmologyRE1-994ENClinical Ophthalmology, Vol 2010, Iss default, Pp 1331-1346 (2010)
institution	DOAJ
collection	DOAJ
language	EN
topic	Ophthalmology RE1-994
spellingShingle	Ophthalmology RE1-994 Nicholas P Bell Jos&eacute; L Ramos Robert M Feldman Safety, tolerability, and efficacy of fixed combination therapy with dorzolamide hydrochloride 2% and timolol maleate 0.5% in glaucoma and ocular hypertension
description	Nicholas P Bell, Jos&eacute; L Ramos, Robert M FeldmanRobert Cizik Eye Clinic, Department of Ophthalmology and Visual Science, The University of Texas Medical School at Houston, Houston, Texas 77030, USAAbstract: Glaucoma is a collection of diseases characterized by multifactorial progressive changes leading to visual field loss and optic neuropathy most frequently due to elevated intraocular pressure (IOP). The goal of treatment is the lowering of the IOP to prevent additional optic nerve damage. Treatment usually begins with topical pharmacological agents as monotherapy, progresses to combination therapy with agents from up to 4 different classes of IOP-lowering medications, and then proceeds to laser or incisional surgical modalities for refractory cases. The fixed combination therapy with the carbonic anhydrase inhibitor dorzolamide hydrochloride 2% and the beta blocker timolol maleate 0.5% is now available in a generic formulation for the treatment of patients who have not responded sufficiently to monotherapy with beta adrenergic blockers. In pre- and postmarketing clinical studies, the fixed combination dorzolamide&ndash;timolol has been shown to be safe and efficacious, and well tolerated by patients. The fixed combination dorzolamide&ndash;timolol is convenient for patients, reduces their dosing regimen with the goal of increasing their compliance, reduces the effects of &ldquo;washout&rdquo; when instilling multiple drops, and reduces the preservative burden by reducing the number of drops administered per day.Keywords: dorzolamide, timolol, glaucoma, ocular hypertension, elevated IOP, fixed combination therapy
format	article
author	Nicholas P Bell Jos&eacute; L Ramos Robert M Feldman
author_facet	Nicholas P Bell Jos&eacute; L Ramos Robert M Feldman
author_sort	Nicholas P Bell
title	Safety, tolerability, and efficacy of fixed combination therapy with dorzolamide hydrochloride 2% and timolol maleate 0.5% in glaucoma and ocular hypertension
title_short	Safety, tolerability, and efficacy of fixed combination therapy with dorzolamide hydrochloride 2% and timolol maleate 0.5% in glaucoma and ocular hypertension
title_full	Safety, tolerability, and efficacy of fixed combination therapy with dorzolamide hydrochloride 2% and timolol maleate 0.5% in glaucoma and ocular hypertension
title_fullStr	Safety, tolerability, and efficacy of fixed combination therapy with dorzolamide hydrochloride 2% and timolol maleate 0.5% in glaucoma and ocular hypertension
title_full_unstemmed	Safety, tolerability, and efficacy of fixed combination therapy with dorzolamide hydrochloride 2% and timolol maleate 0.5% in glaucoma and ocular hypertension
title_sort	safety, tolerability, and efficacy of fixed combination therapy with dorzolamide hydrochloride 2% and timolol maleate 0.5% in glaucoma and ocular hypertension
publisher	Dove Medical Press
publishDate	2010
url	https://doaj.org/article/abf43b91af4442e783570dc823038032
work_keys_str_mv	AT nicholaspbell safetytolerabilityandefficacyoffixedcombinationtherapywithdorzolamidehydrochloride2andtimololmaleate05inglaucomaandocularhypertension AT josampeacutelramos safetytolerabilityandefficacyoffixedcombinationtherapywithdorzolamidehydrochloride2andtimololmaleate05inglaucomaandocularhypertension AT robertmfeldman safetytolerabilityandefficacyoffixedcombinationtherapywithdorzolamidehydrochloride2andtimololmaleate05inglaucomaandocularhypertension
_version_	1718402614166552576

Safety, tolerability, and efficacy of fixed combination therapy with dorzolamide hydrochloride 2% and timolol maleate 0.5% in glaucoma and ocular hypertension

Ejemplares similares